Blood Cancer Program
Blood Cancer Program
Blood Cancer Program
Blood Disorders & Hematology Program
Researchers at The University of Texas Health Science Center at San Antonio (UT Health San Antonio), reporting this week in the journal Proceedings of the National Academy of Sciences, identified a mechanism through which two antiviral genes, when mutated, promote a childhood cancer called pediatric myelodysplastic syndrome (MDS). Scientists at Oklahoma State University and Cornell University collaborated […]
Approximately 30% of individuals with myeloid malignancy diseases have a mutation in a certain gene called tet methylcytosine dioxygenase 2 (TET2). This gene is responsible for providing instructions on creating certain proteins and is known to have a tumor-suppressive function. A study published October 2 in Nature is the first to explain the pathway […]
Ruben A. Mesa, MD, FACP, executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, has played a key role as both an investigator and aiding the drug development for the past eight years to get RoPEG INFa2b (besremi) approved in PV.
Yu Luan, PhD, assistant professor in the Department of Cell Systems and Anatomy in the Joe R. and Teresa Lozano Long School of Medicine at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) received a UT System Rising STARs (Science and Technology Acquisition and Retention) award in the amount […]